[HTML][HTML] Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
… Nine studies comprising 1698 patients with NSCLC were included in this meta-analysis, of
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …
[HTML][HTML] Erlotinib-loaded dendrimer nanocomposites as a targeted lung cancer chemotherapy
… Comparative in situ study showed that cationic G4 erlotinib-… to neutral G5 erlotinib-loaded
dendrimers and erlotinib alone. These … The aim of this work is to design non-invasive erlotinib …
dendrimers and erlotinib alone. These … The aim of this work is to design non-invasive erlotinib …
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ
… Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG)
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
[HTML][HTML] Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis
XY Liu, HN Pan, Y Yu - World Journal of Gastrointestinal Surgery, 2024 - ncbi.nlm.nih.gov
… Nevertheless, the results of this study showed that erlotinib combined with chemotherapy
significantly prolonged the PFS of pancreatic cancer patients compared with chemotherapy …
significantly prolonged the PFS of pancreatic cancer patients compared with chemotherapy …
Erlotinib complexation with randomly methylated β-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer
… The purpose of this study was to investigate the impact of anticancer drug erlotinib-randomly …
Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD …
Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD …
Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights
SH K. P, TD Babu, P C. M, G Joshy… - Free Radical …, 2022 - Taylor & Francis
… Antioxidant properties of plant extracts: an EPR and DFT comparative study of the
reaction with DPPH, TEMPOL and spin trap DMPO. J Braz Chem Soc. 2009;20(8):1483–1492. …
reaction with DPPH, TEMPOL and spin trap DMPO. J Braz Chem Soc. 2009;20(8):1483–1492. …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
… The results of the present study demonstrated that erlotinib was dominated by afatinib and
gefitinib, while afatinib had an ICER estimate of $34,879 per LY gained or $46,506 per QALY …
gefitinib, while afatinib had an ICER estimate of $34,879 per LY gained or $46,506 per QALY …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
… Study subjects and data collection This study included 599 patients with EGFR-mutant
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
[HTML][HTML] In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692
O Dömötör, M Mathuber, CR Kowol - European Journal of Pharmaceutical …, 2024 - Elsevier
… Hereby, we report on an extensive comparative study of three approved FGFR inhibitors and
KP2692 regarding their proton dissociation processes, lipophilicity and their HSA and AGP …
KP2692 regarding their proton dissociation processes, lipophilicity and their HSA and AGP …
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response …
K Nakagawa, EB Garon, L Gao, S Callies… - Cancer chemotherapy …, 2022 - Springer
… Observed exposure parameters for erlotinib are shown in Online Resource 2. Erlotinib PK
… Distribution of erlotinib exposure parameters in plasma were generally similar between the …
… Distribution of erlotinib exposure parameters in plasma were generally similar between the …